Enanta Pharmaceuticals, Inc.ENTANASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-12.50%
↓ 429% below average
Average (39q)
3.80%
Historical baseline
Range
High:32.60%
Low:-19.23%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -12.50% |
| Q2 2025 | -3.05% |
| Q1 2025 | 1.48% |
| Q4 2024 | -10.14% |
| Q3 2024 | 7.08% |
| Q2 2024 | -19.23% |
| Q1 2024 | -2.16% |
| Q4 2023 | 0.56% |
| Q3 2023 | -15.87% |
| Q2 2023 | -1.11% |
| Q1 2023 | 6.27% |
| Q4 2022 | 17.55% |
| Q3 2022 | -10.98% |
| Q2 2022 | -7.12% |
| Q1 2022 | -13.31% |
| Q4 2021 | -0.81% |
| Q3 2021 | 4.15% |
| Q2 2021 | 13.22% |
| Q1 2021 | 13.20% |
| Q4 2020 | -0.06% |
| Q3 2020 | 5.78% |
| Q2 2020 | 6.35% |
| Q1 2020 | -0.51% |
| Q4 2019 | -15.34% |
| Q3 2019 | 12.36% |
| Q2 2019 | 0.90% |
| Q1 2019 | -2.07% |
| Q4 2018 | 29.55% |
| Q3 2018 | -5.49% |
| Q2 2018 | 32.60% |
| Q1 2018 | 19.61% |
| Q4 2017 | 8.77% |
| Q3 2017 | 7.19% |
| Q2 2017 | 18.48% |
| Q1 2017 | 3.82% |
| Q4 2016 | 8.92% |
| Q3 2016 | 6.63% |
| Q2 2016 | 17.96% |
| Q1 2016 | 1.22% |
| Q4 2015 | 28.15% |